[EN] SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS<br/>[FR] ANALOGUES DE SPIROAMINOOXAZOLINE EN TANT QUE MODULATEURS DE RÉCEPTEUR ADRÉNERGIQUE ALPHA2C
申请人:SCHERING CORP
公开号:WO2010042475A1
公开(公告)日:2010-04-15
In its many embodiments, the present invention provides a novel class of spiroaminooxazoline analogues as modulators of α2C adrenergic receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.
Cascade Michael-Intramolecular Transesterification-Elimination Reaction of 3,4-Dihydro-3-nitrochromen-2-ones and β,γ-Unsaturated α-Oxo Esters: An Efficient Access to 2-Pyrone Derivatives
Multisubstituted 2-oxopyran-6-carboxylic acid derivatives were synthesized under mild reaction conditions through a base-promoted reaction between 3,4-dihydro-3-nitrochromen-2-ones and β,γ-unsaturatedα-oxoesters to give products in excellent yields. The reaction is believed to proceed through a cascadeMichael–intramoleculartransesterification–elimination process.
Processes for the preparation of biologically active chromanones are disclosed, including processes for the preparation of intermediates useful in the preparation of the biologically active chromanones. The chromanones and the intermediates disclosed herein may be useful for a variety of therapies, including the treatment of various cancers and the treatment of inflammation and inflammation related disorders.
Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments
申请人:Auckland Uniservices Limited
公开号:US07989451B2
公开(公告)日:2011-08-02
The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I
and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments
申请人:Hay Michael Patrick
公开号:US20090186886A1
公开(公告)日:2009-07-23
The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I
and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.